Arcus Biosciences Inc’s recent filing unveils that its Chief Financial Officer Goeltz II Robert C. unloaded Company’s shares for reported $53910.0 on Dec 31 ’24. In the deal valued at $15.00 per share,3,594 shares were sold. As a result of this transaction, Goeltz II Robert C. now holds 60,138 shares worth roughly $0.83 million.
Then, Goeltz II Robert C. bought 3,594 shares, generating $53,910 in total proceeds.
Before that, Azoy Alexander sold 201 shares. Arcus Biosciences Inc shares valued at $3,079 were divested by the Chief Accounting Officer at a price of $15.32 per share. As a result of the transaction, Azoy Alexander now holds 19,070 shares, worth roughly $0.26 million.
H.C. Wainwright initiated its Arcus Biosciences Inc [RCUS] rating to a Neutral in a research note published on October 21, 2024; the price target was $20. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early October with a ‘”an Overweight”‘ rating. BofA Securities began covering RCUS with “Neutral” recommendation on November 18, 2022. Morgan Stanley started covering the stock on October 11, 2022. It rated RCUS as “an Overweight”.
Price Performance Review of RCUS
On Tuesday, Arcus Biosciences Inc [NYSE:RCUS] saw its stock fall -0.79% to $13.82. Over the last five days, the stock has lost -7.06%. Arcus Biosciences Inc shares have fallen nearly -7.19% since the year began. Nevertheless, the stocks have fallen -20.35% over the past one year. While a 52-week high of $20.31 was reached on 01/07/25, a 52-week low of $13.51 was recorded on 01/13/25. SMA at 50 days reached $15.74, while 200 days put it at $16.04.
Levels Of Support And Resistance For RCUS Stock
The 24-hour chart illustrates a support level at 13.60, which if violated will result in even more drops to 13.37. On the upside, there is a resistance level at 14.09. A further resistance level may holdings at 14.35. The Relative Strength Index (RSI) on the 14-day chart is 33.12, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.94%. Stochastics %K at 12.08% indicates the stock is a buying.
How much short interest is there in Arcus Biosciences Inc?
A steep rise in short interest was recorded in Arcus Biosciences Inc stocks on 2024-12-31, dropping by -0.28 million shares to a total of 7.75 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 8.03 million shares. There was a decline of -3.62%, which implies that there is a negative sentiment for the stock.
